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OBJECTIVES: Contradicting results have been demonstrated for the expression of the epidermal growth factor
receptor (EGFR) as a prognostic marker in non–small cell lung cancer (NSCLC). The complexity of the EGF system
with four interacting receptors and more than a dozen activating ligands is a likely explanation. The aim of this
study is to demonstrate that the combined network of receptors and ligands from the EGF system is a prognostic
marker. MATERIAL AND METHODS: Gene expression of the receptors EGFR, HER2, HER3, HER4, and the ligands
AREG, HB-EGF, EPI, TGF-α, and EGF was measured by quantitative polymerase chain reaction in tumor samples
from 100 NSCLC patients without EGFR activating mutations. Results were dichotomized into high or low levels of
target expression. Coexpression of the ligands and receptors was observed, and a score was developed based on
the summed effect of receptors and ligands. Akaike’s information criteria selected the optimal score. Results were
correlated with age, sex, stage, histology, performance status, and overall survival. RESULTS: Patients were
randomly split 1:1 to create test and validation cohorts. In multivariate analyses, the only individual prognostic
marker was EPI (hazard ratio [HR] 0.38 [0.20-0.72], P = .003). The optimal score in the test cohort was validated as
a marker of inferior survival in the validation cohort and by bootstrapping. Multivariate analysis confirmed the
combined score as a prognostic marker of inferior survival (HR 3.75 [2.17-6.47], P b .00001). CONCLUSION: Our
study has developed a model that takes the complexity of the EGF system into account and shows that this model
is a strong prognostic marker in NSCLC patients.
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http://dx.doi.org/10.1016/j.tranon.2016.05.002Despite advances in the treatment, non–small cell lung cancer
(NSCLC) remains the leading cause of cancer-related death in the
world [1]. In particular, the overall prognosis is poor for the metastatic
stages, with a median overall survival (OS) of only 8 to 10 months.
Even in the early nonmetastatic stages, the 5-year survival rate is as
low as 50% [2,3]. Prognostic markers are needed to stratify patients
with different risk outcome. Several biomarkers have been evaluated
in NSCLC, but only a few have proven to be clinically relevant. An
activating mutation in the epidermal growth factor receptor (EGFR) is
both a well-described predictive marker of benefit of EGFR-targeted
tyrosine kinase inhibitors but also a debated prognostic marker of
better OS [4–9]. As EGFR expression has been associated with OS in
head and neck, colorectal, and esophagus cancer [10–12], attention
has been directed toward the use of EGFR expression as a prognostic
marker in NSCLC, but contradicting results have been demonstrated[13–16]. The EGF system is complex, and the effect of
ligand-receptor interaction depends on a variety of different factors,
which provides a plausible explanation for the divergence observed
between studies that only evaluate EGFR expression in general.
EGFR is one out of four related receptors from the EGF system and is
Figure 1. Patient selection.
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other receptors when activated by a ligand. Several ligands from the
EGF system such as amphiregulin (AREG), epidermal growth factor
(EGF), and transforming growth factor–α (TGF-α) only activate
EGFR, whereas some have the ability to activate several combinations
of the four EGF receptors like heparin-binding epidermal growth
factor (HB-EGF), epiregulin (EPI), and betacellulin (BCL). Most
knowledge on the role of the ligands in NSCLC is from in vitro
studies or from smaller clinical studies. In vitro studies have suggested
that the biological effect of EGFR activation is dependent on the
specific activating ligand as well as the dimerization partner [17]. Yet,
no clinical studies have evaluated the effect of the network of
receptors and ligands influencing EGFR in NSCLC. Furthermore,
the majority of the clinical studies exploring EGFR expression are
based on immunohistochemistry which is a semiquantitative method
with a great risk of interobserver variability. Quantitative gene
expression analyses provide a more accurate measure and are therefore
more suitable for studies comparing expression levels. Prospectively,
we have collected fresh tumor samples from patients suspected of lung
cancer. Accordingly, the aim of this study is to evaluate the gene
expression of the network of receptors and ligands of the EGF system
affecting EGFR as a prognostic markers in NSCLC.
1. Materials and Methods
1.1. Patients and Tumor Samples
In this study, 1093 patients referred to the Department of
Pulmonary Medicine, Aarhus University Hospital, Denmark, for
diagnostic workup of lung cancer were included consecutively from
April 2011 until January 2013. Patients with NSCLC without
mutations in EGFR defined the NSCLC group used in this study.
Patients with other types of cancer than NSCLC were excluded. To
establish normal values of gene expression, a reference group was
made of patients without cancer, as they had comparable clinical
features (age, smoking history, clinical symptoms, and anamnestic
symptoms leading to lung cancer suspicion). Patient selection is
depicted in Figure 1. Clinicopathological characteristics were
collected at time of inclusion. To minimize the risk of positive
overestimation when establishing a score, the NSCLC group was
randomly split 1:1 into a test and a validation cohort matched on
histology, stage, WHO performance status (PS), and sex.
All patients gave informed written consent before inclusion, and
the study was approved by the Central Denmark Region Committees
on Biomedical Research Ethics (M-20100246).
Tumor samples were collected at time of diagnosis with the
Ultra-micro sampling technique, allowing an aliquot of the diagnostic
sample to be used for gene expression studies [18]. Samples were
stored in RNAprotect at −80°C until total RNA extraction.
1.2. RNA Extraction and cDNA Preparation
Total RNA was extracted from all tissue samples using the RNeasy
micro kit from Qiagen, (Qiagen, Hilden, Germany; www.qiagen.com)
according to the instructions of the manufacturer. Purified RNA was
diluted in 14 μl of RNase-free H2O. cDNA was synthesized from 2 μl
of total RNA in a 20-μl reaction, following manufacturer’s instructions
(Applied Biosystems Inc., CA).
1.3. Quantitative Polymerase Chain Reaction (PCR)
Expression of EGFR, HER2, HER3, HER4, AREG, HB-EGF, EPI,
TGF-α, EGF, and the reference gene β-actin was quantified using theLightCycler 480 instrument. The PCR was performed using SYBR
Green I Master Mix Buffer except HER2 that was analyzed by
hydrolysis probes (SYBR Green RT-PCR Reagents Kit, Roche,
Mannheim, Germany) following manufacturer’s instructions. Primer
sequences, concentrations, and annealing temperature are shown in
Table S1. All primers were purchased from Eurofins MWG Synthesis
GmbH, Ebersberg, Germany. In an earlier study, we found that, in
these samples, β-actin was the most stable household gene [18].
Therefore, each target gene was normalized to the household gene
β-actin and used for further analysis.
1.4. Cut Points
A cut point was determined in the reference group for each target
gene. The cut point was defined by the mean + 2 SD for the
individual target gene, and expression levels above the cut points were
defined as elevated.
1.5. The EGF Score Model
To evaluate the EGF system as a network, a score based on the
summed effect of each receptor and ligand was established. Each
ligand and receptor were given the value of +1 or −1 based on the
individual markers’ hazard ratio (HR) in the univariate analysis in the
test cohort [19]. If the HR was greater than 1, the value given was +1,
and if the HR was less than 1, the value was −1. The sum of all
markers created the score. The score was then confirmed by
bootstrapping (1000 times) to create bias-corrected confidence
intervals (BCIs). Redundancy of one or several markers was tested
to optimize the score. To select the score with the best model fit to
explain the data, Akaike’s information criteria (AIC) were calculated
in the test cohort for every combination excluding one or several of
the markers. When the difference of the AIC values was larger than 2,
Table 1. Clinical Characteristics
Test Cohort
n = 50
Validation
Cohort n = 50
PValues*,† Reference Cohort
n = 111 (282 Samples)
PValues*,‡
Age
mean (min-max)
66.4
(37-86)
68.7
(50-86)
.21 60.7
(21-84)
b .001
Sex n (%)
Female 30 (60) 20 (40) .05 51 (46) .51
Male 20 (40) 30 (60) 60 (54)
Smoking
Never 2 1 .23 28 b .001
Former 26 32 59
Current 22 17 24
PS n (%)
0 21 (42) 15 (30) .24
1 17 (34) 27 (54)
2 10 (20) 7 (14)
3 2 (4) 1 (3)
Stage
I & II 11 (22) 9 (18) .44
III & IV 39 (78) 41 (82)
Histology
Squamous 15 (30) 12 (24) .50
Nonsquamous 35 (70) 38 (76)
Sample origin
Tumor 18 (36) 11 .12 34 .02
Lymph node 32 (64) 39 248
* P values calculated by Person χ2 or t test.
† Test cohort versus validation cohort.
‡ Reference cohort versus test and validation cohorts.
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AIC was less than 2, the score with the least target genes was selected
[20]. Based on the calculated AIC, the score with the best model fit in
the test cohort was chosen and validated in the validation cohort. By
bootstrapping (1000 times), the optimal score was validated. After
validation, a multivariate analysis was carried out in the entire
NSCLC group taking clinicopathological characteristics into account.
1.6. Statistical Analysis
Associations between clinical characteristics were tested by Person χ2
or t test. Survival was calculated from date of diagnosis until date of
death or last day of follow-up (May 1, 2015).OSwas defined as death of
any cause or last date of follow-up. OS was estimated by the
Kaplan-Meier method and compared by the log-rank test. Uni- and
multivariate HRs were estimated by Cox proportional hazard analyses.
HR is presented with a 95% CI. All P values are two-sided with a 5%Table 2. Characteristics of the EGF System
Univariate Multivariate *
Biomarker Cut Point HR CI P Value HR CI
HER1 0.20 0.98 0.48-2.00 .754 1.06 0.65-1.72
HER2 6.40 1.25 0.38-4.09 .707 1.97 0.77-4.99
HER3 0.12 0.91 0.57-1.46 .710 1.01 0.50-2.07
AR 1.03 2.03 0.93-4.44 .077 1.34 0.81-2.22
EPI 0.25 0.56 0.31-1.02 .060 0.38 0.20-0.72
HB-EGF 1.20 1.92 1.11-3.31 .018 1.86 0.96-3.59
TGFα 0.20 0.29 0.07-1.20 .086 0.59 0.27-1.32
EGF 0.35 0.22 0.05-0.91 .037 0.99 0.55-1.78
The initial score ‡ 2.31 1.26-4.56 .008 2.17 1.11-4.22
The optimized score ‡ 3.70 2.26-8.08 .00001 2.62 1.49-4.61
* Multivariate results are adjusted for age, sex, PS, stage, and histology.
† Number of patients with upregulated biomarker.
‡ Results are presented with bias-corrected interval.significance level. The proportional hazard assumption was assessed
graphically by plotting Schoenfeld residuals and log-log plots.
Bootstrapping was used for validation of estimated HR. Bias in the
bootstrap-derived calculations was used as an indicator of robustness of
estimates. To identify effect modification, interaction terms were
established and added to the regression model. Backward selection was
used to identify the multivariate model with best fit. Variables were
stepwise removed until only significant variables remained (P b .10).
Model fit was evaluated by AIC. Statistical analyses were carried out in
STATA version 13.
2. Results
2.1. Patient Characteristics
Clinical and pathological characteristics are detailed in Table 1.
One hundred patients with NSCLC without EGFR mutations and
111 patients without cancer were included. From the NSCLC
patients, a test cohort (n = 50) was randomly generated with a similar
distribution of age, stage, PS, and histologic subtype as the total
cohort. In the reference cohort, the mean age was lower (60.7) than in
the cancer cohorts (67.5) and the distribution of never smokers versus
current or former was significantly different. Furthermore, in the
reference cohort, more samples originated from lymph nodes
compared with the primary tumor than in the cancer cohorts.
2.2. The EGF System
Reference group: 282 samples each representing individual lesions
from 111 patients were examined, and a cut point for each target gene
was calculated as described above. Because this part of the study was
carried out to characterize the background expression of the target
genes, all available samples from each patient were included. Cut
points are shown in Table 2.
NSCLC group: Level and distribution of each target gene are shown
in Figures 2 and S1 and in Table 2. For the receptors EGFR andHER3
and the ligands, elevated levels were observed in both nonsquamous and
squamous cell type and predominantly in the advanced stages. For EPI
andHB-EGF, the distribution between histological types was not equal.
EPIwas elevated in 7%of patients with squamous cell histology (2 of 27)
as opposed to 23% (17 of 73) in patients with nonsquamous histology.
For HB-EGF, the corresponding frequencies were 29% (8 of 27) in
squamous cell and 15% (11 of 73) in nonsquamous cell. HER4 wasScore Value Nonsquamous (n = 73) Squamous (n = 27)
Stage I & II
(n = 12)
Stage III & IV
(n = 61)
N (%)
Stage I & II
(n = 7)
N (%)
Stage III & IV
(n = 20)
N (%)
P Value Initial Score N † (%) N † (%) N † (%) N † (%)
.826 −1 1 (8) 24 (39) 3 (42) 5 (25)
.155 +1 0 4 (7) 1 (14) 0
.959 −1 0 9 (15) 1 (14) 2 (10)
.254 +1 0 19 (31) 0 6 (30)
.003 −1 1 (8) 16 (26) 0 2 (10)
.065 +1 0 8 (13) 2 (29) 9 (45)
.203 −1 1 (8) 8 (13) 1 (14) 2 (10)
.991 −1 1 (8) 14 (23) 3 (43) 2 (10)
.02
.001 0 (0) 12 (20) 1 (14) 8 (40)
Figure 2. HER1/β-actin levels. Dashed line indicates the cutoff value defined in the reference group. Patients are split by stage: I and II
versus III and IV.
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elevated HER4 mRNA. Therefore, HER4 was not included in further
analyses.HER2was found in 72 of 100 samples, and yet, only 5 patients
had samples with elevated expression comparedwith the reference group.
2.3. Survival Analyses
In a univariate Cox proportional hazards model, gene expression of
all target genes was analyzed for the potential of being an individual
prognostic marker (Table 2). This demonstrated that overall EGFR
gene expression was not a prognostic marker (HR 0.98 [0.48-2.00]; P =
.75) as opposed to EGF (HR 0.35 [0.05-0.91]; P = .037) andHB-EGF
(HR 1.2 [1.11-3.31]; P = .018). However, neither of the associations
was significant when tested in a multivariate analysis taking known
prognostic clinicopathological characteristics into account. For EPI, the
opposite was found. In a multivariate analysis, high gene expression
levels of EPI were found to be a marker of better prognosis (HR 0.38
[0.20-0.72]; P = .003). None of the remaining receptors were
significant prognostic markers when analyzed individually.
2.4. Score Development
Values creating the initial score are listed in Table 2. The initial
score was tested and validated by bootstrapping demonstrating that
the score could predict an inferior OS (HR 2.31, BCI [1.26-4.56]).
To optimize the initial score, it was tested if one or several of the
markers were excessive. Therefore, different combinations were tested
in the test cohort. Based on the AIC, the score with the optimal model
fit only included the ligands AREG, HBEGF, EPI, and TGF-α. In
the test cohort as well as in the validation cohort, the optimized score
was a prognostic marker of inferior OS (test: HR 6.17, 95% CI
[2.60-14.64], P N .001, BCI [1.94-18.89]; validation: HR 2.41, 95%
CI [1.23-4.71], P = .01, BCI [1.92-18.61]) (illustrated in Figure 3).
In the entire NSCLC group, the optimized score was tested in a
multivariate analysis adjusting for the clinical parameters age, sex, PS,stage, and histology. The optimized score was a significant prognostic
marker of inferior outcome (HR 2.93 [1.64-5.23], P b .0001, BCI
[1.68-4.97]) as seen in Table 3. Median survival for patients with a
high score was 4.7 months (95% CI: 2.9-8.3) versus 15.9 months
(95% CI: 11.5-22.0) for patients with a low score.
3. Discussion
The impact of EGFR expression on OS in NSCLC is controversial.
Studies evaluating EGFR expression as a prognostic marker have
presented contradicting conclusions [13–16]. In a meta-analysis by
Nakamura et al., expression of the EGFR was not a prognostic marker
in NSCLC [13] as opposed to what has been found in other cancers
[10–12]. In vitro studies have indicated that it is not EGFR in itself
but the summed effect of the EGF system that leads to tumor growth
[17]. In certain studies, coexpression of the other receptors from the
EGF system has been evaluated as a prognostic factor, though without
convincing results when known clinical confounders are taken into
consideration [21–23]. Expression of the complete network of ligands
and receptors interacting with EGFR has not been evaluated as a
prognostic factor in NSCLC.
In concordance with the complexity of the EGF system, we have
evaluated the gene expression of each receptor and ligand in 100
NSCLC patients EGFR wild type in a model. We found that this
model predicts the outcome of the individual patient, whereas the
individual receptor or ligand does not. Our findings support the
hypothesis that it is not the individual receptor or ligand but the
network that is reflected in the OS. Gene score models have been used
in several settings to sum the effect of several markers that may be
coexpressed but differ in impact on a given outcome [19,24,25]. We
show by internal validation that our model is a strong prognostic
marker in NSCLC patients even when the known clinical
characteristics are taken into account. We also demonstrate that it
is the increased expression of the ligands AREG, HB-EGF, EPI, and
Figure 3. Kaplan-Meier Survival curves for OS in the test cohort (A) and the entire cohort (B). Differences between groups were calculated
using the log-rank test.
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summed effect of the system because removing the effect of the
receptors increases the fit of the model. To our knowledge, this has
not previously been demonstrated in clinical samples. When
establishing the score, we chose an arbitrary approach giving each
marker the value of +1 or −1 and not the actual coefficient as is done
elsewhere [19]. Because of to the small sample size, the actual
coefficient for the individual marker is not reliable, especially when
splitting into test cohorts of only 50. Optimizing the estimate would
lead to a risk of overfitting, and therefore, we chose −1 or +1 as
coefficients. By doing so, we accept the risk of not being able to
incorporate the magnitude of each factor of the EGF system, but in
contrast, we do not run the risk of assigning inaccurate coefficients.
A major challenge in explorative gene expression studies is to establish
normal values of expression. We identified 111 patients affected by
symptoms leading to lung cancer suspicion but where the diagnosis was
excluded based on a biopsy from a relevant area of the lung or lymph
node. Because of to the consecutive nature of the study, the reference
group is younger and there are more never smokers in this group. Despite
these differences, we believe the reference group to be valid because it
reflects the everyday clinical setting. From the reference group, cut pointsTable 3. Multivariate Cox Proportional Hazard
HR 95% CI P Value HR * 95% CI * P Value * BCI
EGF score 3.52 2.00-6.20 b .001 3.75 2.17-6.47 b .0001 2.09-6.45
Age: ≤67 vs N67 1.28 0.80-2.04 .304
Sex: female vs male 0.85 0.54-1.32 .462
PS: 0, 1 vs 2, 3 1.89 1.06-3.37 .030 1.97 1.14-6.47 .014 1.02-4.01
Stage: I & II vs III & IV 4.16 1.92-9.03 b .001 3.63 1.71-7.68 .001 1.47-8.19
Histology: squamous
vs nonsquamous
0.72 0.42-1.24 .24
Results from the multivariate analysis including the optimized EGF score.
* Significant results using backward selection. Removal criterion: P b .10.were defined, resulting in a test where expression above the cut points
could be interpreted as truly elevated. Subsequently, we evaluated the
prognostic value of the receptors EGFR, HER2, and HER3 and the
ligands AREG, HB-EGF, EPI, TGF-α, and EGF. We found that only
EPI was a prognostic marker of longer OS, whereas none of the
receptors or the remaining ligands were significant predictors of outcome
in amultivariate analysis taking the clinicopathological characteristics into
account. This contradicts other studies [26,27]. In a study by Sunaga et
al., it was shown that high EPI expression could predict inferior outcome
especially in KRAS-mutated patients [27]. It is known that 25% to 30%
of NSCLC patients are expected to have a mutation inKRAS. TheKRAS
mutation status of our patients is unknown, which might explain the
contradictory results. Our ability to find a correlation could also be
explained by the definition of the cut points.We have used biopsies from
patients entering the clinic with symptoms resembling lung cancer to
define the cut points, whereas other studies exploring the role ofEPI have
used either the mean or median value of gene expression [27,28] or
predefined percentages of cancer cells expressingEPI[24,25,29]. By using
our approach, we address the fact that the EGF system is not exclusively
cancer related but also involved in other biological processes likely to take
place in normal tissue (i.e., inflammation, etc.). Furthermore, the samples
used in this study were collected with the intent to perform gene
expression studies compared with studies where mRNA was extracted
from archived formalin-fixed, paraffin-embedded samples.
Despite being unique in this regard, our study faced some limitations.
Firstly, the cohort used in this study was consecutively collected, but
stages I and II were underrepresented (19 patients), just as only 27 of the
patients had squamous histology which was less than expected. We
found no effect modification between the score and histology (data not
shown), indicating that the expression of ligands had an equal effect in
the squamous cell type as well as the nonsquamous EGFR wild-type
patient. Secondly, though affecting EGFR, the receptor HER4 and the
ligand BTC were not included in the final score model. HER4 was
Translational Oncology Vol. 9, No. 4, 2016 Gene Expression of the EGF System Sandfeld-Paulsen et al. 311measurable only in 1 of 50 patients in the test cohort; it was not deemed
relevant. In the literature, only a few studies have evaluated BTC in
clinical samples, and because of limited tissue amount, we chose not to
include it in this study. Our findings seem promising, but they need to
be validated in an independent cohort. A better understanding of the
role of EGFR in NSCLC patients without activating mutations in the
EGFR can help generate new strategies for treatment development
and perhaps improve the OS for NSCLC patients.
4. Conclusion
It is well established that activation of EGFR is dependent on ligands
and other receptors of the EGF system. Therefore, to evaluate EGFR
as a prognostic marker, it is necessary to take these surrounding
ligands and receptors into account. In this study, we show by internal
validation that a score combining factors from the EGF system can be
developed and that the primary impact on OS is increased expression
of the ligands and not the receptors. We have demonstrated a strong
prognostic marker that can identify a group of patients where
different treatment strategies may be needed.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2016.05.002.
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